30-Second Overview: On July 1, 2026, a Taiwan regulation called the Administrative Rules for Using Human Drugs on Dogs, Cats, and Non-Economic Animals is set to take effect. Of the 701 approved human drugs on the government's list, only 144 have completed registration as "animal protection drugs." Medical gases — oxygen, carbon dioxide, nitrogen — are at zero. On April 9, over 100,000 pet owners signed a petition to delay the rule. On April 10, the Ministry of Agriculture convened an emergency cross-ministry meeting and pledged that "if implementation proves unworkable in practice, it will not be rushed through." This isn't a 2026 problem. It's a ten-year legal gap that began with a 2012 counterfeit-drug case, was accidentally thrown open by Legislator Kao Chia-yu in 2022, and was complicated by a first-ever conviction in 2024. Taiwan now has three million registered dogs and cats treated as family members, and a legal framework that still largely assumes they are livestock. This article keeps five voices speaking at once. The author does not synthesize them for you.
✦ A note on format: This article uses a main narrative with named perspective panels. The main thread is the timeline; the perspective panels give voice to five basis vectors — a veterinarian, the pharmacists' association, a legislator, the regulatory agency, and pet owners. These five voices neither contradict nor confirm each other. They are simply placed side by side. You won't find the usual "both sides have a point" synthesis at the end, and you won't find the author stitching them into a single answer. This is Taiwan.md's first attempt at promoting multiple viewpoints from a callout aside into named standalone blocks — a small step from an opinionated Single Source of Truth toward something more like a container of diverse truths.
On the morning of April 10, 2026, the Animal and Plant Health Inspection Agency of Taiwan's Ministry of Agriculture convened a meeting room: representatives from the Food and Drug Administration, the Veterinary Medical Associations of the Republic of China, and the Pharmacists Association of the ROC[^1].
The chair was the agency's director-general. But the real protagonists in that room were two phrases: "human drug" and "animal protection drug."
The day before — April 9 — more than 100,000 pet owners had signed a petition on Taiwan's Public Policy Online Participation Platform, demanding that the government delay the implementation of a rule called the Administrative Rules for Using Human Drugs on Dogs, Cats, and Non-Economic Animals[^2]. The rule was jointly issued by the Ministry of Agriculture's Animal and Plant Health Inspection Agency and the Food and Drug Administration on February 26, 2024, and was set to take effect on July 1, 2026 — giving drug wholesalers more than two years to re-register their products as "animal protection drugs."
Those two years had passed. Of the 701 approved human drugs on the list, only about 144 had been registered as "animal protection drugs"[^3]. Medical gases commonly used in emergency rooms — oxygen, carbon dioxide, nitrogen — were all at zero.
A veterinarian's social-media post had been widely shared by pet owners: "In theory, you can drive to a 24-hour pharmacy at midnight to buy oxygen. In practice — does your neighborhood have a 24-hour medical-gas pharmacy within 30 minutes?"
The question has no good answer. Its bad answer is the "next month" and "next year" Taiwan has been saying for a decade.
This isn't a 2026 problem. It's a box that began opening in a 2012 counterfeit-drug case, was thrown wide by a legislator in 2022, and has not been closed as of today.
The island now has 3 million registered dogs and cats treated as family members, and a legal framework that still basically assumes they are livestock[^4]. The gap between those two realities is where this article enters.
Around that gap, at least five voices are speaking. They are not describing the same problem.
One Pharmaceutical Affairs Act, Two Eras
Taiwan's Pharmaceutical Affairs Act (藥事法) was enacted in 1970 and first substantially revised in 1979[^5]. In that era, the word "pet" barely existed in legal vocabulary. Dogs watched the house, cats caught mice. "Animal drugs" meant drugs for pigs, cows, chickens, ducks, and geese — that is, economic animals.
Article 50 of the Act therefore restricts the sale of prescription drugs to licensed pharmaceutical wholesalers or parties approved by health authorities — not veterinary clinics. Article 33 further restricts drug company sales representatives to marketing only to pharmacies, hospitals, clinics, and public health centers.
Veterinary clinics are not hospitals. From the perspective of this 1970s law, they're not.
In 2015, Article 4 of the Animal Protection Act (動物保護法) was amended to add a critical clause: "When drugs needed to treat animal diseases are insufficient, human drugs designated by the central authority may be used."[^6]
The problem is that this clause conflicts directly with Article 50 of the Pharmaceutical Affairs Act. The Animal Protection Act says "you may use them." The Pharmaceutical Affairs Act says "you cannot buy them." A 2015 clause and a 1970s framework were bound together in the same legal system without ever being introduced to each other.
For ten years, the gap between them has been the tightrope every animal clinic in Taiwan walks each day.
2012: A Drug Wholesaler's Counterfeit Business
The gap did not open in 2015. It was already at work in 2012.
That year, media reports exposed a drug wholesaler who was manufacturing counterfeit animal drugs and selling them to more than a hundred animal hospitals across Taiwan[^7]. The Council of Agriculture's Bureau of Animal and Plant Health Inspection and Quarantine (the predecessor of today's agency) and the Food and Drug Administration both launched investigations. This was the first time Taiwan's public could see what veterinary drug use actually looked like.
An uncomfortable fact surfaced: veterinarians' drug cabinets were full of "human drugs" and "parallel imports." A German heart medication called Pimobendan took more than a decade between its global launch and its legal import into Taiwan. For those entire ten years, every heart-disease dog in Taiwan was being treated with parallel imports[^8].
This was not the illegal behavior of a few rogue veterinarians. It was an open secret across the entire industry.
Perspective │ Veterinarian Chen Ling: Drugs Are Just Drugs
Chen Ling is the director of Yuanye Animal Specialty Hospital, the author of We'll All Be Okay: Scenes from the Veterinary Life Nobody Sees, and one of the founding members of Taiwan's Veterinary Union preparatory committee. When she wrote her essay in UDN Opinion — "Unworkable Rules, Overlooked Animal Drug Controversies: A Practicing Veterinarian's Observations" — she was writing from a double position: a front-line clinician who dispenses drugs every day, and a long-time labor-rights activist in her profession[^9]. In her hospital, only three antibiotics are fully legal for companion animals: cephalexin, Baytril, and cefovecin. Most other antibiotics common around the world are registered in Taiwan only in livestock formulations — dosages that, for a three-kilogram cat, are essentially bombs.
Chen once wrote a line that has since been repeated across Taiwan's veterinary community:
"Drugs are just drugs."
Her meaning: biology does not recognize the human/animal drug distinction. Only the law does.
In her essay she names two drugs. One is Pimobendan, the German heart medication whose legal import gap lasted more than a decade — years in which every Taiwanese heart-disease dog was treated with parallel imports. The other is Palladia (toceranib), an FDA-approved targeted therapy for canine mast-cell tumors that has no Taiwan registration at all. Using it means breaking the law; the Animal Drug Management Act provides for up to seven years' imprisonment for using unapproved animal drugs.
Chen argues that veterinarians receive five years of pharmacology and clinical drug training, yet this training counts for nothing in the eyes of the law — because veterinary clinics are not "medical institutions" and veterinarians cannot buy prescription human drugs directly from wholesalers. Her summary was colder than angry:
"A skilled cook cannot make a meal without rice."
She treats the regulatory framework as a value judgment, not a technical failure. In her reading, the state has quietly accepted that animal lives are not worth full medical care — and that acceptance is written into the structure of the law itself.
2018: The First Draft and Its Civil War
In 2018, the Council of Agriculture published the first draft of the Administrative Rules for Using Human Drugs on Dogs, Cats, and Non-Economic Animals[^10]. The draft opened 600 human drugs to veterinary use, but required that animal clinics not buy directly from wholesalers. They had to route the purchase through a pharmacy — the intermediary.
This draft ignited a professional war that has not ended in six years.
On June 5, 2019, the Pharmacists Association of the ROC held a press conference opposing the draft. Their core argument: medical-pharmaceutical separation (醫藥分業) is the cornerstone of Taiwan's healthcare system, and this principle should not have an animal-medical carve-out. Animal clinics should prescribe; pharmacies should dispense. That is the correct design[^11].
On June 17, 2019, the ROC Veterinary Medical Association issued its own statement. It said two things. First, veterinarians would accept a human-drug distribution-tracking system. Second, they asked the pharmacists' association to "please leave the animals an open road to health."[^12]
That second sentence became the veterinary community's signature line in this dispute.
On June 18, 2019, the FDA stepped in to mediate between the two associations and reached a three-point consensus: clarify the interpretation of current law, develop a small-animal prescription format, and re-review which of 597 already-approved drugs had existing veterinary licenses[^13].
And then the 2018 draft sat there, stuck in controversy, for six years.
Perspective │ The Pharmacists Association of the ROC: We're Not the Ones Blocking It
In April 2026, the Pharmacists Association of the ROC clarified one thing to People News Net: the rule had been finalized back in 2024 with a two-year grace period, and pharmacists were "collaborators, not opponents" of using human drugs for animals[^14].
What they were pushing back against was a particular public reading: the framing that took "701 drugs on the list, only 144 registered" and translated it as "the pharmacists' association blocked registration." The association's position is that registration is a matter between drug wholesalers and the regulatory agency — not pharmacists. Why aren't wholesalers registering? Because the dog-and-cat market is too small. Redesigning packaging, removing the human-drug insert, relisting — the costs may exceed expected revenue. This is administrative lethargy plus market logic, a double failure that has nothing to do with the pharmacists' association.
Underneath the phrase "medical-pharmaceutical separation," the association has a deeper argument: more than 70% of all human antibiotics consumed in Taiwan eventually end up in animals[^15]. If animal clinics can buy drugs directly without a pharmacist in the loop, antimicrobial resistance will only get worse. For them, this isn't a turf war. It's a principle — that drug dispensing needs a third-party check, and that principle should not change based on whether the patient is human or animal.
The rhetorical structure the association used at its 2019 press conference is essentially the same one it uses in 2026: "We don't oppose veterinarians using human drugs. We oppose bypassing the management framework of the Pharmaceutical Affairs Act."
In their April 2026 statement they put it more bluntly: "Administrative lethargy caused the low registration rate. It wasn't pharmacists blocking anything."
2022: The Box a Legislator Opened
In late April 2022, Legislator Kao Chia-yu (高嘉瑜) posted on Facebook. The trigger was a complaint from a woman named Lin: her dog, Angel, had been diagnosed with a tumor and was being treated at Eden Animal Hospital in Taipei in late 2021. The veterinarian had used a drug called Palladia — an FDA-approved canine mast-cell tumor targeted therapy that has no Taiwan registration. Angel died of acute kidney failure[^16].
Kao's post accused the veterinarian of using "illegal drugs." She may have assumed this was a straightforward legal matter: illegal is illegal.
The post detonated.
Veterinary communities, pet-owner communities, animal welfare groups, even the families of heart-disease and cancer dogs who had been using parallel imports for years — they all piled onto Kao. One comment, widely circulated, went: "Legislator, you're going to get the dogs we're saving killed!"[^17]
Kao eventually deleted the post, publicly apologized, and acknowledged that she had "accidentally opened a Pandora's box."[^18] She immediately convened a cross-ministry coordination meeting with the Veterinary Medical Association, the Bureau of Animal and Plant Health Inspection, and animal welfare groups. Three agreements came out of it: loosen import conditions for unapproved animal drugs, accelerate administrative review timelines, and set up a "Pet Emergency Human Drug Treatment Platform"[^19].
This political accident turned out to be the largest push for animal-drug reform in a decade. Not because the resulting policy was particularly good, but because a problem that had been submerged for years suddenly surfaced.
But one thing in the story deserves to be said out loud: Ms. Lin was not accusing an innocent veterinarian of a crime he had to commit to save lives. She believed her dog had been killed by an unapproved drug. Three years later, the Taipei District Court agreed with her.
Perspective │ Legislator Kao Chia-yu: I Got the Point Wrong
In interviews after the incident, Kao told NOWnews: "I accidentally opened Pandora's box."[^20]
She also admitted that her initial questioning of the veterinarian "got the point wrong." She had thought the problem was "a veterinarian using illegal drugs." The real problem, she came to understand, was that under current law, veterinarians cannot legally use the drugs they need. The veterinarian she questioned may have broken the law. But if he hadn't, the dog he treated might have died sooner.
At the coordination meeting that followed, she made a promise to the pet owners in the room: "If your hospital won't give you the drug, call me."[^21]
That sentence is a legislator using personal political capital to patch a structural hole. It was more efficient than any cross-ministry negotiation — and it is also, by itself, evidence of a broken system. A functioning system doesn't require pet owners to call a legislator in the middle of a medical emergency.
Kao's follow-up actions helped push the official rule out the door in February 2024. In some real sense, the current regulation is the chain reaction of her Facebook post that night.
In this one event she played four roles at once: accuser, unwitting harm-doer, mediator, and reform driver. These four roles cannot be collapsed into a single identity. They should not be.
August 2024: The Verdict on Angel
In August 2024, the Taipei District Court delivered its verdict in Ms. Lin's case. It became Taiwan's first criminal conviction of a veterinarian for animal death caused by unapproved drug use[^22].
The court found that the veterinarian had administered an unapproved cancer medication to Angel without proper consent, and that the dosage was contested. Angel died of acute kidney failure. Prosecutors also suspected that the drug involved might have been counterfeit.
After the verdict, Ms. Lin said: "Angel was with me for many years. Now the court has given us both justice."[^23]
She also received Taiwan's first-ever whistleblower reward from the animal-drug inspection system — NT$150,000.
This verdict matters because it complicates the standard narrative in an important way. The dominant story of the last ten years has been: veterinarians use parallel imports to save lives, and unreasonable laws force them to break the law. That story is broadly true. But Angel's case reminds everyone that not every parallel-import case is a life-saving act. Some are professional negligence, dosage misjudgment, or worse.
In other words: loosening the law doesn't only free well-meaning veterinarians. It also lets unaccountable misuse slide. The pharmacists association's insistence on "third-party checking" suddenly has a concrete supporting case.
Angel's case proves two things at once. The current law traps well-meaning veterinarians in illegality. And when genuine medical malpractice occurs, the current law is a pet owner's only tool to hold someone accountable. A law that simultaneously protects the wrong and protects the right — that is the full shape of this gap.
2024: A New Rule and Its Two-Year Grace Period
On February 26, 2024, the Ministry of Agriculture's Animal and Plant Health Inspection Agency and the FDA jointly published the official version of the Administrative Rules for Using Human Drugs on Dogs, Cats, and Non-Economic Animals, scheduled to take effect July 1, 2026[^24]. The gap between publication and implementation — two years and four months — was a grace period: time for drug wholesalers to redesign packaging, remove the human-drug insert, and register their products as "animal protection drugs."
The new rule uses a two-track design. Drugs registered as "animal protection drugs" can be supplied directly from wholesalers to animal clinics. Drugs not registered must be purchased by the pet owner, who brings a "purchase certificate" from the veterinarian to a pharmacy.
In theory, this is a compromise between the medical-pharmaceutical separation principle and the reality of animal emergencies.
In practice, the compromise collapsed under the registration rate.
As of April 2026, only about 144 of the 701 listed drugs had been registered — less than 30 percent[^25]. Medical gases were at zero.
Perspective │ The Regulatory Agency's Middle Ground
The Animal and Plant Health Inspection Agency has never issued a public statement admitting that it is stuck. But from a decade of negotiation records and the official statements surrounding the April 10, 2026 cross-ministry meeting, the agency's position becomes legible:
It is not a legislative body; it cannot amend the Pharmaceutical Affairs Act. It is not the regulator of medical-pharmaceutical separation; it cannot decide whether animal clinics can buy from wholesalers. It is not the regulator of drug wholesalers; it cannot order anyone to register[^26].
What it can do has a common feature: it requires other agencies to cooperate.
On April 9, 2026, facing the pressure of a 100,000-signature petition, the Ministry of Agriculture gave the media an official line: "If implementation proves unworkable in practice, it will not be rushed through."[^27]
That sentence simultaneously admits that the rule may not take effect on schedule, and refuses to commit to any specific alternative. Two messages live in the same line, because honestly, that's all the agency is in a position to say.
The agency's middle ground is not a pose. It is a structural position. It is pinned to the conference table by a 1970s law, a 2015 clause, a 3-million-pet market too small to attract pharmaceutical investment, two competing professional associations, and 100,000 pet owners who refuse to lose their family members — and every direction pulls a different way.
This is not an efficiency problem. It is a structural problem.
144 Out of 701
Unpacking these two numbers:
701 is the total number of human drugs the government has approved for use in dogs and cats. This list alone took ten years to negotiate. 144 is the number of drugs that have actually been registered as "animal protection drugs" — the ones that wholesalers can supply directly to animal clinics. The remaining 557 are on the approved list but unregistered by wholesalers, which means pet owners have to bring a "purchase certificate" to a pharmacy and pay for them there. The registration count for medical gases — oxygen, carbon dioxide, nitrogen — is zero[^28].
Medical gases are among the most commonly used consumables in animal emergency care. Pulmonary edema, traffic accidents, anesthesia monitoring — all require oxygen. If on July 1, when the new rule goes live, an animal clinic has no oxygen in inventory, its emergency department becomes legally inoperable on paper.
The number 144 means different things in different frames. To the pharmacists association, it's wholesaler and administrative lethargy. To the veterinary associations, it's a failure of policy design. To pet owners, it's the concrete possibility that their family member will arrive at the ER and wait for a drug that isn't there.
All three readings are true. They aren't three descriptions of the same thing — they are three facts in three different coordinate systems.
Perspective │ The Pet Owners' Petition: My Dog Is My Family
In early April 2026, a petition was filed on the Public Policy Online Participation Platform titled "Petition to Amend the Pharmaceutical Affairs Act to Remove the 'Human Drug' Framing, and to Delay the July 1 Animal Rule Until the Amendment Is Complete."[^29] It crossed 100,000 signatures in three days — the largest civic mobilization in the history of Taiwan's animal-drug controversy.
The petition's main argument is not a workaround. It asks to amend the Pharmaceutical Affairs Act itself — to tear down the "human drug as the architectural core" framing from the foundation rather than patch it. The petitioners' position: if a legal system wants to handle animal medical care, it has to be redesigned at the architectural level, not grafted onto human-drug supplementary clauses.
Not one of the 100,000 signatories is an "expert." They are ordinary people with a heart-disease dog, a diabetic cat, an epileptic puppy, or a cancer-stricken elderly cat at home. They do not need to read the Pharmaceutical Affairs Act and the Animal Protection Act side-by-side to know one thing: if on July 1, their pet arrives at the ER and there is no drug, that is a reality they cannot accept.
The emotional tone of the petition is not anger. It is fear. Pet owners do not care which association is "right." They care whether their family members will survive the next emergency.
There is a crucial word in their position: "family." Under Taiwanese law, pets are still "property," and property under the Civil Code has no emergency-treatment needs. The 100,000-signature petition is, in effect, a demand that the legal system recognize one thing: Taiwan already has a large population — 3 million animals plus their owners — living a double identity of "legally property, personally family." That double identity is the bedrock of this controversy. Animal drugs is simply its most recent earthquake.
How Other Countries Handle This
Taiwan isn't the first country to hit this gap. Other countries also have three million pets, also have the "market too small for registration" logic, also have veterinarians who want to use human drugs in emergencies. Their solutions are different.
The United States: AMDUCA, 1994
Before 1994, U.S. law was close to where Taiwan is now: any veterinary use of an FDA-approved drug outside of the approved label (different species, dose, or route) was illegal. This is called "extralabel use," and before 1994 it was prohibited. In 1994, the U.S. Congress passed the Animal Medicinal Drug Use Clarification Act (AMDUCA), formally allowing veterinarians to use human prescription drugs, human OTC drugs, and even compounded preparations on animals — under the condition that a valid Veterinarian-Client-Patient Relationship (VCPR) is in place[^30].
AMDUCA's core design is not "publishing a bigger list." It is "using the professional relationship as the gatekeeper." Within the VCPR framework, the veterinarian is responsible. No item-by-item registration needed. The legal framework hands trust to the veterinarian's clinical judgment, while requiring that judgment to take place inside a traceable professional relationship.
The American logic: pharmaceutical companies will never register enough drugs for animal use, because the market is too small. Rather than making registration the only legal pathway, make the professional relationship the legal pathway.
Japan: One Law for Both
Japan places animal drugs and human drugs under a single law — the Pharmaceuticals and Medical Devices Act (formerly the Pharmaceutical Affairs Act). Veterinarians or the operators of animal treatment facilities are exceptionally permitted to manufacture or import animal drugs for diagnosis, treatment, or prevention of animal disease. "If problems arise, the veterinarian bears responsibility."[^31]
The feature of the Japanese model is that a single law covers both human and animal drugs. The two don't fall into a gap between two warring statutes. Taiwan's Animal Protection Act Article 4 and Pharmaceutical Affairs Act Article 50 are independent of each other — their connection has to be stitched together by yet another administrative rule. Japan's architecture wrote both under one roof from the start.
What Taiwan Chose
Taiwan does not lack international models. AMDUCA is public. The Japanese model has been cited in policy discussions for a decade. Taiwan chose a third path: build a 701-drug list, require wholesalers to register item by item as "animal protection drugs," preserve the pharmacists' inspection role inside the medical-pharmaceutical separation framework, and simultaneously acknowledge that animal clinics need an emergency exception.
The logic of that path is political compromise, not institutional reason. It has to satisfy the pharmacists' association, the veterinary association, pet owners, drug wholesalers, animal welfare groups, the Animal Plant Health Inspection Agency, the FDA, and the legislature — all at once. What everyone can accept is a list. And the registration rate for that list is twenty percent.
Not every country has to walk the same road. The problem is that Taiwan has been walking this one for ten years and hasn't finished.
The Cold Arithmetic of the Market
Outside all these voices, there is one more player that does not speak but influences everything: the market.
Taiwan has 3 million registered dogs and cats. Using the global animal drug market size of US$47.88 billion as a reference, Taiwan's pet market — including food, medical care, supplies, and services — is around NT$50 billion, of which about 20% (around NT$10 billion) is medical care[^32].
That's a big number to ordinary ears. For an international pharmaceutical company, it is roughly one-tenth of Japan's market and one-twentieth of America's[^33].
Pharmaceutical decision-making works like this: bringing a drug to market in any country requires regulatory registration, clinical trial data translation, packaging redesign, distributor contracts, and post-market surveillance. These costs are fixed, regardless of whether the company expects to sell a million units or a hundred billion.
If projected sales fall below a fixed multiple of these fixed costs, the company exits the market.
For most animal-specific drugs, Taiwan's dog-and-cat market sits well below that exit threshold.
This is why Article 4 of the Animal Protection Act opens up human drugs in the first place: because animal drug markets will always be too small to attract local development. Human drugs are a form of free-riding — they let animals share the benefits of human-scale markets.
This is also why veterinarians have used parallel imports for years. Parallel imports are another form of free-riding — they pull drugs from Japanese, American, and European markets back to this small island.
This is also why only 144 of the 701 drugs are registered. For a wholesaler, the cost of redesigning packaging and re-registering a drug may exceed the entire annual sales of that drug in Taiwan's dog-and-cat market.
This is not administrative failure. It is economics.
But it does not let the system off the hook. The question is not "why don't wholesalers register?" The question is "why does a system that knows the market is too small to produce a high registration rate make registration the only legal channel in the first place?"
This question cannot be answered by the market. Only by politics.
Drugs Are Just Drugs, Drugs Are Not Just Drugs
Chen Ling wrote: "Drugs are just drugs."
It is a clinician sitting in her animal hospital, facing a full apparatus of laws, associations, drafts, petitions, and a decade of standoff, answering all of it in one sentence. Drugs are just drugs: biology does not recognize the human/animal distinction, only the law does.
But Chen herself knows that drugs are not just drugs.
Drugs are a market. Three million pets cannot fund the research and development of dedicated veterinary pharmaceuticals.
Drugs are a professional boundary. Pharmacists and veterinarians are two professional identities, with two laws from two different eras behind them.
Drugs are politics. The Pharmaceutical Affairs Act was written in 1970, the Animal Protection Act Article 4 was amended in 2015. Between those two statutes lies an entire transformation in how Taiwan understands "what an animal is."
Drugs are emotion. Among the names of three million dogs and cats, not a single one is called "property."
Whether the July 1, 2026 regulation takes effect on schedule is being decided right now in meeting rooms at the Ministry of Agriculture. But whether it takes effect, or is postponed, or is delayed for another decade, two things will probably not change:
This island treats pets as family.
And this island treats pet medicines as commodities.
✦ This island treats pets as family. And this island treats pet medicines as commodities. Those two sentences are not a contradiction — they are two basis vectors.
These two sentences are not a contradiction. They are two basis vectors. Which projection you want to live in is your choice.
This article does not choose for you. It opens the space, so you can see that it is not a line — it is at least a five-dimensional room, with a voice speaking from every wall.
Further Reading
- Taiwan's Stray Animal Culture — From "Twelve Nights" to zero-kill policy: how this island relearned what to do with the lives in its streets. The other end of the animal-drug controversy is how Taiwan has been redefining the very status of "animal"
- Zoo and Performing Animal Ethics in Taiwan — Another field where human society argues about "medication and care" of animals: different chapter, same problem
- Taiwan's National Health Insurance — The other end of human pharmaceutical regulation: the world's largest national healthcare experiment, with no institutional bridge to animal medicine. The "medical-pharmaceutical separation" principle discussed in this article was built during the NHI era
- Taiwan's Disaster Medical System — Human emergency medicine has a floor: 119, emergency response networks, DMAT. Animal emergency care doesn't have anything like that floor. Read side-by-side to see the resource gap between two systems
References
[^1]: UDN: Cheat Sheet — Will the July Pet Drug Rule Be Finalized Today? Live Link and Voices From All Sides — Agenda and participating agencies for the April 10, 2026 cross-ministry meeting, with background context on public sentiment before and after.
[^2]: PChome News: Pet Drug Rule Controversy — 100,000 Signature Petition Demands Delay; Agency Closed-Door Meeting Criticized as Opaque — The April 9, 2026 petition crossing 100,000 signatures demanding delay, and civic group criticism of the closed-door format.
[^3]: Mombaby: Can't Medicate Even With a Prescription? 2026 Pet Drug Rule Cheat Sheet — 8,000 Pet Parents Signing in Anxiety — Concrete numbers on the 701 drugs with only ~144 registered, zero medical gas registration, and veterinary association warnings about emergency care collapse.
[^4]: Ministry of Agriculture: Recent Development of Taiwan's Pet Industry and Management Measures — Official statistics on Taiwan's more than 3 million registered dogs and cats, overall pet industry scale, and household pet ownership rates.
[^5]: Laws and Regulations Database: Pharmaceutical Affairs Act — History of the act: enacted 1970, first major revision 1979. Full text of Article 50 (prescription drug sales channel restrictions) and Article 33 (drug sales representative restrictions).
[^6]: Laws and Regulations Database: Animal Protection Act — 2015 amendment adding Article 4: "When drugs needed to treat animal diseases are insufficient, human drugs designated by the central authority may be used."
[^7]: Plain Law Movement: Human Drugs and Parallel Imports — A Decade-Long Veterinary Controversy — The 2012 counterfeit animal drug case in full, historical analysis of the veterinary drug market structure, and background on parallel imports and human drug use.
[^8]: Wuo-Wuo: The "Medicine-Pharmacy Divorce Ring" — A Dossier of the Veterinary Human-Drug Controversy — A full timeline compiled by Wuo-Wuo, including the Pimobendan ten-year gap, the Palladia legal gray zone, and the phases of regulatory efforts since 2014.
[^9]: UDN Opinion: Chen Ling / Unworkable Rules, Overlooked Animal Drug Controversies: A Practicing Veterinarian's Observations — Chen Ling's first-person account of the clinical drug shortage, the limits of cephalexin, Baytril, and cefovecin, the unsuitability of livestock formulations for small animals, and her "drugs are just drugs" and "a skilled cook cannot make a meal without rice" framings.
[^10]: The News Lens: Can Animals Be Treated with Human Drugs? Kao Chia-yu's Pandora's Box Drew Fire from Vets and Pet Owners — Content of the 2018 first-draft rule, the 600-drug opening list, and full context on the subsequent professional standoff.
[^11]: Liberty Times: Pharmacists Association Reaffirms Support for the Human-to-Animal Drug Rule; Wildlife Protection Groups Demand Indefinite Delay — The official position of the Pharmacists Association of the ROC, insistence on medical-pharmaceutical separation, and rebuttal to claims that "pharmacists blocked registration."
[^12]: Wuo-Wuo: The "Medicine-Pharmacy Divorce Ring" — The June 17, 2019 ROC Veterinary Medical Association statement, including the "please leave the animals an open road to health" line.
[^13]: People News Net: Pharmacists Association Clarifies — Administrative Lethargy, Not Pharmacists, Caused Low Registration Rate — The association's public argument that administrative lethargy is responsible for the low registration rate, and the three-point consensus reached on June 18, 2019.
[^14]: People News Net — The association's emphasis that "the rule was finalized in 2024 with a two-year grace period," and its "collaborator, not opponent" self-characterization.
[^15]: Wuo-Wuo: One Medical Dispute That Accidentally Revealed the Veterinary Drug Problem — Statistics showing more than 70% of human antibiotic usage in Taiwan ends up in animals, antimicrobial resistance supervision arguments, and the pharmacists' emphasis on third-party inspection.
[^16]: TVBS: Opening Pandora's Box — Kao Chia-yu's Prohibited-Drug Accusation Against Veterinarian Draws Backlash, Apology — Full account of Legislator Kao's late-April 2022 Facebook post accusing a veterinarian of illegal drug use, and her subsequent deletion and apology.
[^17]: Liberty Times: Kao Chia-yu's Accusation Draws Fire, Deletion Fails to Quell Backlash, Lawyer Points Out Practical Dilemma — The reaction from pet-owner and veterinary communities, lawyer commentary on the legal reality, and records of the "you're going to get the dogs we're saving killed" comment.
[^18]: NOWnews: Questioning Triggers Veterinary Drug Controversy — Kao Chia-yu: "I Accidentally Opened Pandora's Box" — Kao's post-incident reflection, formally acknowledging the "Pandora's box" phrasing.
[^19]: ETtoday Pet Cloud: Kao Chia-yu Convenes Emergency Meeting After Accusation, Promises Pet Owners "If the Hospital Won't Give You the Drug, Call Me" — Full record of the cross-ministry coordination meeting, three-point consensus (loosening import conditions, accelerating review times, emergency pet-drug platform).
[^20]: NOWnews — Source for Kao's "accidentally opened Pandora's box" and her "got the point wrong" self-critique.
[^21]: ETtoday Pet Cloud — The "if the hospital won't give you the drug, call me" political-patch record, and the three-point consensus content.
[^22]: Liberty Times: Prohibited Drug Killed Dog — First Veterinarian Conviction, Owner Says "Court Gave Us Justice" — August 2024 Taipei District Court verdict on the Angel case, the first criminal conviction in Taiwan for animal death caused by unapproved drug use, and Ms. Lin's receipt of the first-ever NT$150,000 whistleblower reward from the animal drug inspection system.
[^23]: Liberty Times — Source for Ms. Lin's "Angel was with me for many years" quote and the case details on Palladia, acute kidney failure, and the counterfeit suspicion.
[^24]: Animal and Plant Health Inspection Agency: Pet Emergency Human Drug Treatment Platform — Official document recording the February 26, 2024 publication of the finalized Administrative Rules for Using Human Drugs on Dogs, Cats, and Non-Economic Animals, the two-year grace period, and the July 1, 2026 implementation date.
[^25]: UDN: Pet Drug Rule in Cross-Agency Discussion Today — Civic Groups Call for End to Professional Turf War — Registration progress as of April 2026 — only 144 of 701 drugs registered — and the Animal Welfare Monitoring Alliance's demand that animal welfare groups and pet owners be included in consultation.
[^26]: Legislative Yuan: Research Analysis on the Controversy Over Animal Use of Human Drugs — The Legislative Yuan Legal Bureau's policy analysis of the interplay among the Pharmaceutical Affairs Act, the Animal Protection Act, and the Animal Drug Management Act.
[^27]: TaroNews: Human Drugs for Dogs and Cats — Ministry of Agriculture: "Will Not Rush It If Implementation Is Unworkable" — Source for the April 9, 2026 official "will not rush it if implementation is unworkable in practice" line.
[^28]: Vocus: 2026 Pet Drug Rule — "The Current System Isn't Protecting Animals, It's Stopping Them From Being Saved" — Veterinarian concerns about the inability to access medical gases in time, emergency-care scenarios requiring immediate oxygen, and the "no 24-hour medical gas pharmacy within 30 minutes" argument.
[^29]: Public Policy Online Participation Platform: Petition to Amend the Pharmaceutical Affairs Act and Delay the July 1 Animal Rule — Source for the April 2026 petition's structure and demands, and the official record of crossing 100,000 signatures.
[^30]: American Veterinary Medical Association: Animal Medicinal Drug Use Clarification Act (AMDUCA) — Official AVMA explanation of AMDUCA's core principles, the VCPR framework, the extralabel use authorization conditions, and the US regulatory landscape before and after 1994.
[^31]: Japan Ministry of Agriculture, Forestry and Fisheries: Overview of Japan's Animal Pharmaceutical System — Official overview of Japan's animal drug regulatory system, including the Pharmaceuticals and Medical Devices Act's unified treatment of human and animal drugs, and the veterinarian/animal clinic operator exception for manufacture and import.
[^32]: Global Bio-Business Monthly: 30% of Taiwanese Households Have Pets, Market Size Over NT$50 Billion — Hopes for an End-to-End Supply Chain — Market analysis of Taiwan's pet industry at more than NT$50 billion, 28.05% household ownership rate, 8.89% annual growth rate, and the structural breakdown with pet food at 50%.
[^33]: CIO Taiwan: The Pandemic Unexpectedly Accelerated Global Pet Economic Development — Global animal drug market size of US$47.88 billion, 5.4% compound annual growth rate, and comparison data between the Taiwanese and international markets.